n-186 Search Results


nbqx disodium salt  (Alomone Labs)
91
Alomone Labs nbqx disodium salt
Nbqx Disodium Salt, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/NBQX+disodium+salt/alomone+labs___n-186
Average 91 stars, based on 1 article reviews
nbqx disodium salt - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
supermix for probes  (Bio-Rad)
99
Bio-Rad supermix for probes
Supermix For Probes, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/Droplet+PCR+Supermix/pmc12721614-193-23-26
Average 99 stars, based on 1 article reviews
supermix for probes - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
broth  (DSMZ)
86
DSMZ broth
Broth, supplied by DSMZ, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/Rhodotorula+bacarum/pmc03364525-129-17-28
Average 86 stars, based on 1 article reviews
broth - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
e2 vaginal insert  (TherapeuticsMD)
90
TherapeuticsMD e2 vaginal insert
E2 Vaginal Insert, supplied by TherapeuticsMD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/tx+004hr/pm30238814-3-7-22
Average 90 stars, based on 1 article reviews
e2 vaginal insert - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
dba fluorescent staining quantification  (KNIME GmbH)
90
KNIME GmbH dba fluorescent staining quantification
Dba Fluorescent Staining Quantification, supplied by KNIME GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/dba+fluorescent+staining+quantification/pmc10539341__41467_2023_40948_MOESM1_ESM-18-9-26
Average 90 stars, based on 1 article reviews
dba fluorescent staining quantification - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
gene sets biocarta  (BioCarta)
90
BioCarta gene sets biocarta
Gene Sets Biocarta, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/biocarta+gene+sets/pm37612728-261-28-32
Average 90 stars, based on 1 article reviews
gene sets biocarta - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cheminform  (Verlag GmbH)
90
Verlag GmbH cheminform
Cheminform, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/cheminform/10__1002_slash_chin__201103281-369-2-13
Average 90 stars, based on 1 article reviews
cheminform - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
corox otw 75 up/steroid  (Biotronik GmbH)
90
Biotronik GmbH corox otw 75 up/steroid
Corox Otw 75 Up/Steroid, supplied by Biotronik GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/corox/pm21232629-36-49-55
Average 90 stars, based on 1 article reviews
corox otw 75 up/steroid - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
parecoxib  (Dynastat Inc)
90
Dynastat Inc parecoxib
Parecoxib, supplied by Dynastat Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/parecoxib/pmc11957830-15-0-15
Average 90 stars, based on 1 article reviews
parecoxib - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
marburg heart score  (Marburg GmbH)
90
Marburg GmbH marburg heart score
Marburg Heart Score, supplied by Marburg GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/marburg+heart+score/pmc06827655-174-27-29
Average 90 stars, based on 1 article reviews
marburg heart score - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
balb/c nude mice  (Japan SLC inc)
90
Japan SLC inc balb/c nude mice
Balb/C Nude Mice, supplied by Japan SLC inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/balb+c+mice/pm29626524-57-6-18
Average 90 stars, based on 1 article reviews
balb/c nude mice - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
sglt2i  (TriNetX Inc)
90
TriNetX Inc sglt2i
Characteristics of the included studies
Sglt2i, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/n-186/sglt2i/pmc10949729-24-11-42
Average 90 stars, based on 1 article reviews
sglt2i - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Characteristics of the included studies

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Characteristics of the included studies

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques:

Characteristics of participants in the included studies

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Characteristics of participants in the included studies

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques:

Antidiabetic drugs used by patients in the included studies

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Antidiabetic drugs used by patients in the included studies

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Medications

Findings from the main analysis. A Odds of all-cause mortality with SGLT2i + GLP-1RA combination therapy versus SGLT2i or GLP-1RA therapy. B Changes in BMI with combination therapy at the baseline versus the 6-month follow-up. C Changes in SBP with combination therapy at the baseline versus the 6-month follow-up. D Changes in total cholesterol with combination therapy at the baseline versus the 6-month follow-up. E Changes in eGFR with simultaneous combination therapy at the baseline versus the 6-month follow-up. F Changes in HbA1c with combination therapy at the baseline versus the 6-month follow-up. G Changes in FPG with combination therapy at the baseline versus the 6-month follow-up. BMI Body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, M–H Mantel–Haenszel, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i Sodium–glucose transport protein 2 inhibitor

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Findings from the main analysis. A Odds of all-cause mortality with SGLT2i + GLP-1RA combination therapy versus SGLT2i or GLP-1RA therapy. B Changes in BMI with combination therapy at the baseline versus the 6-month follow-up. C Changes in SBP with combination therapy at the baseline versus the 6-month follow-up. D Changes in total cholesterol with combination therapy at the baseline versus the 6-month follow-up. E Changes in eGFR with simultaneous combination therapy at the baseline versus the 6-month follow-up. F Changes in HbA1c with combination therapy at the baseline versus the 6-month follow-up. G Changes in FPG with combination therapy at the baseline versus the 6-month follow-up. BMI Body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, M–H Mantel–Haenszel, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i Sodium–glucose transport protein 2 inhibitor

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Filtration, Clinical Proteomics, Standard Deviation

Findings from the subgroup analyses. A Changes in BMI with simultaneous versus sequential combination therapy at the 6-month follow-up. B Changes in SBP with simultaneous versus sequential combination therapy at the 6-month follow-up. C Changes in HbA1c levels with simultaneous versus sequential combination therapy at the 6-month follow-up. D Changes in FPG levels with simultaneous versus sequential combination therapy at the 6-month follow-up. BMI body mass index, CI confidence interval, FPG fasting plasma glucose, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i sodium–glucose transport protein 2 inhibitor, Seq. Combn. Tx sequential combination therapy, Simult. Combn. Tx simultaneous combination therapy

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Findings from the subgroup analyses. A Changes in BMI with simultaneous versus sequential combination therapy at the 6-month follow-up. B Changes in SBP with simultaneous versus sequential combination therapy at the 6-month follow-up. C Changes in HbA1c levels with simultaneous versus sequential combination therapy at the 6-month follow-up. D Changes in FPG levels with simultaneous versus sequential combination therapy at the 6-month follow-up. BMI body mass index, CI confidence interval, FPG fasting plasma glucose, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i sodium–glucose transport protein 2 inhibitor, Seq. Combn. Tx sequential combination therapy, Simult. Combn. Tx simultaneous combination therapy

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Clinical Proteomics, Standard Deviation

Findings of the GRADE analysis

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Findings of the GRADE analysis

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Comparison